Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Head-to-Head: which JAK inhibitor tames rheumatoid arthritis best?

NCT ID NCT07636057

Disease control Sponsor: Sheikh Zayed Federal Postgraduate Medical Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will compare two drugs, tofacitinib and upadacitinib, added to standard methotrexate treatment for rheumatoid arthritis. One hundred adults in Pakistan will take one of the two drugs daily for six months. Researchers will measure disease activity and side effects to see which drug works better and is safer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tofacitinib and upadacitinib (JAK inhibitors) added to methotrexate
What this could lead to
If this trial succeeds, it could show which JAK inhibitor works better for rheumatoid arthritis in the Pakistani population, helping doctors choose the most effective treatment.
What could go wrong
This is a small, early-stage study with only 100 participants, so results may not apply to everyone. Both drugs have known risks like infections, and the trial hasn't started yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Adult patients aged ≥18 years, regardless of gender Exclusion Criteria: * • Other autoimmune rheumatic disorders (SLE, psoriatic arthritis, AS, etc.) * Administration of any biologic DMARD in the previous three months * History of a serious infection (e.g., active tuberculosis or sepsis) * Previous or existing history of recurrent infections or immunosuppressive status * History of any malignancy in the last five years. * Current chemotherapy, radiotherapy or intake of any genotoxic drug * Severe liver impairment (e.g., ALT/AST \>3× ULN) * Severe renal impairment (e.g., estimated GFR \<30 mL/min) * Severe Haematological Abnormalities: Hb \<8 g/dL, TLC \<3,000 /mm³, Platelets \<100,000 /mm³ * Past or present deep vein thrombosis or pulmonary embolism * Pregnant or lactating women * Women of reproductive age who are not practicing adequate contraception measures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis (RA

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.